Literature DB >> 17116186

Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q(10).

S C Lim1, H H Tan, S K Goh, T Subramaniam, C F Sum, I K Tan, B L Lee, C N Ong.   

Abstract

AIM: Individuals with diabetes and prediabetes are at risk of vascular injury. However, the exact mechanisms are unclear. The mitochondria mobile electron carrier coenzyme Q(10) (CoQ(10)) is a potent lipophilic antioxidant. We hypothesize that oxidative stress, detectable as changes in plasma CoQ(10) concentrations and composition, plays an important role in vascular disease in diabetes.
METHODS: We measured plasma CoQ(10) concentrations (including reduced ubiquinol and oxidized ubiquinone subfractions) in 60 subjects with normal glucose tolerance [NGT; fasting plasma glucose (FPG) < 5.5 mmol/l], 63 with impaired fasting glucose (IFG; FPG 5.6-6.9 mmol/l) and 69 with Type 2 diabetes (DM; FPG > 6.9 mmol/l).
RESULTS: In men and women, the total CoQ(10)/total cholesterol ratio was reduced in DM (mean +/-sd) [male (M) 0.09 +/- 0.04; female (F) 0.07 +/- 0.04] compared with NGT (0.29 +/- 0.08; 0.21 +/- 0.07) and IFG (0.27 +/- 0.07; 0.23 +/- 0.07) (DM vs. NGT and IFG P = 0.001). A stepwise reduction in the plasma ubiquinol fraction (ubiquinol/total CoQ10) was observed from NGT (M 0.93 +/- 0.06; F 0.95 +/- 0.06) compared with IFG (0.43 +/- 0.25; 0.41 +/- 0.15) and DM (0.24 +/- 0.11; F 0.29 +/- 0.16) (DM vs. IFG vs. NGT P = 0.001). In contrast, the plasma ubiquinone/ubiquinol ratio increased from NGT (M 0.08 +/- 0.07, F 0.06 +/- 0.08) to IFG (2.14 +/- 1.84, 1.75 +/- 1.04) to DM (4.77 +/- 4.88, 3.81 +/- 3.71) (DM vs. IFG vs. NGT P = 0.001). These differences remained after adjusting for age, body mass index and FPG.
CONCLUSIONS: The change in CoQ(10) with increasing FPG concentration suggests an increase in oxidative burden, already evident in the prediabetic IFG individuals. This increase in oxidative stress might contribute to the increased risk of vascular disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116186     DOI: 10.1111/j.1464-5491.2006.01996.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  13 in total

1.  Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10.

Authors:  Akira Ishikawa; Hiroo Kawarazaki; Katsuyuki Ando; Megumi Fujita; Toshiro Fujita; Yukio Homma
Journal:  Clin Exp Nephrol       Date:  2010-09-28       Impact factor: 2.801

2.  Oxidative stress, obstructive sleep apnea and cardiovascular disease.

Authors:  Ilker Tasci
Journal:  Sleep Breath       Date:  2011-07-01       Impact factor: 2.816

3.  Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.

Authors:  K Huynh; H Kiriazis; X-J Du; J E Love; K A Jandeleit-Dahm; J M Forbes; J R McMullen; R H Ritchie
Journal:  Diabetologia       Date:  2012-02-29       Impact factor: 10.122

4.  Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy.

Authors:  Orhan Ates; Habip Bilen; Sadullah Keles; H Hakan Alp; Mevlüt Sait Keleş; Kenan Yıldırım; Osman Ondaş; L Can Pınar; Mustafa Civelekler; Orhan Baykal
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

5.  Omental adipocyte hypertrophy relates to coenzyme Q10 redox state and lipid peroxidation in obese women.

Authors:  Thomas Grenier-Larouche; Anne Galinier; Louis Casteilla; André C Carpentier; André Tchernof
Journal:  J Lipid Res       Date:  2015-08-03       Impact factor: 5.922

6.  Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.

Authors:  Marni J Falk; Erzsebet Polyak; Zhe Zhang; Min Peng; Rhonda King; Jonathan S Maltzman; Ezinne Okwuego; Oksana Horyn; Eiko Nakamaru-Ogiso; Julian Ostrovsky; Letian X Xie; Jia Yan Chen; Beth Marbois; Itzhak Nissim; Catherine F Clarke; David L Gasser
Journal:  EMBO Mol Med       Date:  2011-06-08       Impact factor: 12.137

Review 7.  Supplementation of Coenzyme Q10 among Patients with Type 2 Diabetes Mellitus.

Authors:  Qiuhua Shen; Janet D Pierce
Journal:  Healthcare (Basel)       Date:  2015-05-21

8.  Glutaredoxin mediated redox effects of coenzyme Q10 treatment in type 1 and type 2 diabetes patients.

Authors:  Sergio J Montano; Jacob Grünler; Deepika Nair; Michael Tekle; Aristi P Fernandes; Xiang Hua; Arne Holmgren; Kerstin Brismar; Johanna S Ungerstedt
Journal:  BBA Clin       Date:  2015-06-10

9.  Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial.

Authors:  Hoda Zahedi; Shahryar Eghtesadi; Soroush Seifirad; Neshat Rezaee; Farzad Shidfar; Iraj Heydari; Banafsheh Golestan; Shima Jazayeri
Journal:  J Diabetes Metab Disord       Date:  2014-07-25

Review 10.  Mitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome.

Authors:  Md Ashraful Alam; Md Mahbubur Rahman
Journal:  J Diabetes Metab Disord       Date:  2014-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.